Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: Results from a seven-year randomised comparison of low and standard doses

Journal of the British Menopause Society

Volumn 10, Issue 3, 2004, Pages 95-102

  Heikkinen, Jorma ^a   Vaheri, Raija ^b   Timonen, Ulla ^b  

^a OULU DEACONESS INSTITUTE   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Bleeding control; Endometrium; Low dose continuous combined hormone therapy; Medroxyprogesterone acetate; Oestradiol valerate

Indexed keywords

ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; INDIVINA;

ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTHRITIS; ARTICLE; ASTHMA; BACKACHE; BILE DUCT CANCER; BRAIN ARTERY ANEURYSM; BREAKTHROUGH BLEEDING; BREAST CANCER; BRONCHITIS; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; GASTRITIS; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; INSOMNIA; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MIGRAINE; MOOD DISORDER; OVARY CANCER; PHARYNGITIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; STROKE; TREATMENT OUTCOME; VAGINITIS;

DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 9244226018     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/1362180043654647     Document Type: Article

References (17)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 228: 321-333.
2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
4. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 2001; 40: 195-201,
5. Huber JC, Campagnoli C, Druckmann R, et al. Recommendations for estrogen and progestin replacement and postmenopause. Maturitas 1999; 33: 197-209.
6. Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower dose of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75; 6: 1065-1078.
7. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76:13-24.
8. Bruhat M, Rudolf K, Vaheri R, et al. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy. A randomised comparative dose-ranging study. Maturitas 1002; 40: 259-271.
9. Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001; 75: 1080-1087.
10. Heikkinen JE, Vaheri RT, Ahomäki S, et al. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens. Am J Obstet Gynecol 2000; 182: 560-567.
11. Heikkinen J, Vaheri R, Kainulainen P, Timonen U. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal osteoporosis: a comparison of high and low dose estrogen-progestin regimens. Osteoporosis Int 2000; 11: 929-937.
12. Sintonen H, Johansson S, Ohinmaa A, et al. Measuring health-related quality of life in women on hormone replacement therapy. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3: 351-361.
13. Committee for Proprietary Medicinal Products (CPMP). Points to consider on hormone replacement therapy CPMP/EWP/021/97. The European Agency for the Evaluation of Medicinal Products, November 1997.
14. Weiderpass E, Adami H-O, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131-1137.
15. Cancer Incidence in Finland 1998 and 1999. Cancer Statistics of the National Research and Development Centre for Welfare and Health. Cancer Society of Finland, No. 63, Helsinki 2002.
16. Salomaa V, Korhonen HJ, Tuomilehto J, et al. Serum cholesterol distribution, measurement frequency and cholesterol awareness in three geographical areas of Finland. Eur Heart J 1990; 11; 4: 294-301.
17. Salomaa V, Moltchanov V, Keskimäki I, et al. The occurrence of stroke in Finland. Cardiovascular Registers. National Public Health Institute. http://www.ktl.fi/en (accessed 24 May 2004).